Core Viewpoint - The recent stock issuance by Jinbo Biological, controlled by Zhong Shanshan, aims to raise up to 2 billion RMB to support its growth and development in the collagen market, while also indicating a strategic partnership with Yangshengtang [1][2][7]. Group 1: Company Actions and Financials - Jinbo Biological plans to issue no more than 717,566 shares, representing 6.24% of its total shares before the issuance, to raise funds for a humanized collagen protein database and working capital [1][2]. - The total investment for the projects is 200 million RMB, with 57.5% allocated to the collagen protein project and 42.5% for working capital [2]. - Jinbo Biological's stock price has surged since its listing, with a maximum increase of over 800% from its issue price, reaching a peak of 452.29 RMB [3][9]. Group 2: Market Performance and Growth - Jinbo Biological has shown impressive financial growth, with revenue increasing from 233 million RMB in 2021 to 1.443 billion RMB in 2024, and net profit rising from 57.39 million RMB to 732 million RMB in the same period [9]. - The gross margin improved from 82.29% to 92.02%, and net margin increased from 24.38% to 50.68% [9]. - The Chinese collagen market reached 28.7 billion RMB in 2021, growing at 40.7%, with a significant increase in the penetration of recombinant collagen [9]. Group 3: Strategic Partnerships and Future Outlook - Yangshengtang, controlled by Zhong Shanshan, is entering into a strategic partnership with Jinbo Biological, which is expected to enhance business synergies and accelerate the implementation of their strategic goals [7][8]. - The collaboration aims to leverage technological integration and market channel empowerment, potentially leading to significant advancements in product development [7][8]. - Jinbo Biological's need for strategic investors is highlighted by its relatively small size and the increasing competition in the medical aesthetics industry [10][13].

对于医美手术，我们常常怀有一些固有的观念，比如，认为去做医美的人们有些过度关注取悦他人，或是 认为医美的流行导致了审美的趋同。根据今年5月发布的《弗若斯特沙利文：2024年中国轻医美产品行业 白皮书》，2024年中国医美市场规模已经达到了3120亿元，较2023年增长14.8%。中国医美产业正在迅速 崛起。爱美之心人皆有之，医美热的背后，是否体现出了某种对时光流逝的焦虑感？面对老去与死亡的态 度，形塑着我们的当下。播客《在川上》正聚焦生老病死中所隐藏的智慧密码，我们将陆续推出播客节目 中的系列对话。 本期《在川上》，我们邀请到了中国医学科学院整形外科医院的李一琳医生，她同时也是一名医学插画师 （代表作《整形密码》），从一线医生的专业视角，和我们一起探讨了医美手术背后的那些故事与心理。 完整音频节目欢迎搜索"在川上"进行收听。 医美在改善了外表的同时，也让很多人变得更自信 松木：今天聊的主题缘起于去年夏天我的一段在咖啡馆"偷听"的经历，那天和我隔了两张桌子的位置有两 个小姑娘，大概二十多岁，长得非常好看。她们聊天谈到了医美的话题，我就好奇，她们都那么美了，还 在做医美。这也激发了我对医美这一话题的兴趣，能不能先 ...